CIPLA PALBOCICLIB palbociclib 100 mg capsule bottle

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

palbociclib, Quantity: 100 mg

Available from:

Cipla Australia Pty Ltd

Pharmaceutical form:

Capsule, hard

Composition:

Excipient Ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type A; colloidal anhydrous silica; titanium dioxide; purified water; iron oxide yellow; iron oxide red; Gelatin

Administration route:

Oral

Units in package:

21's

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

CIPLA PALBOCICLIB is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: ? an aromatase inhibitor as initial endocrine-based therapy ? fulvestrant in patients who have received prior therapy

Product summary:

Visual Identification: Opaque, size 1 hard gelatin capsules with a caramel cap and light orange body, printed with black ink "Cipla" on the cap and "100 mg" on the body; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Child resistant closure

Authorization status:

Registered